{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:50:26Z","timestamp":1757314226520},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:00:00Z","timestamp":1684540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:00:00Z","timestamp":1684540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Few studies have directly compared the incidence of pneumonia in patients on common chronic obstructive pulmonary disease (COPD) treatments such as long-acting muscarinic antagonists (LAMA) with those on inhaled corticosteroids and long-acting \u03b2<jats:sub>2<\/jats:sub>-agonist (ICS\/LABA). Moreover, risk factors for pneumonia in COPD are still unclear. We aimed to compare the incidence of pneumonia in COPD patients on LAMA and those on ICS\/LABA and explored the risk factors associated with pneumonia. This nationwide cohort study used Korean National Health Insurance claim data from January 2002 to April 2016. Patients who received COPD medication, either LAMA or ICS\/LABA, with the COPD diagnostic code, were selected. We enrolled patients with good compliance (medication possession ratio\u2009\u2265\u200980%). The primary outcome was pneumonia in COPD patients initiating LAMA or ICS\/LABA. We investigated the risk factors associated with pneumonia, including the sub-types of ICS treatments. After propensity score matching, the incidence rate per 1000 person-years of pneumonia was 93.96 for LAMA (n\u2009=\u20091003) and 136.42 for ICS\/LABA (n\u2009=\u20091003) patients (p\u2009&lt;\u20090.001). The adjusted hazard ratio (HR) for pneumonia in patients on fluticasone\/LABA was 1.496 (95% confidence interval [CI] 1.204\u20131.859) compared with LAMA (p\u2009&lt;\u20090.001). In multivariable analysis, a history of pneumonia was a risk factor associated with pneumonia (HR 2.123; 95% CI 1.580\u20132.852; p\u2009&lt;\u20090.001). The incidence of pneumonia was higher in COPD patients on ICS\/LABA compared with those on LAMA. It is recommended that ICS use be avoided in COPD patients with high pneumonia risk.<\/jats:p>","DOI":"10.1038\/s41598-023-35223-3","type":"journal-article","created":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T12:01:58Z","timestamp":1684584118000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD"],"prefix":"10.1038","volume":"13","author":[{"given":"Eung Gu","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youlim","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Il","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Ha","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Yoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Bum","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin Kook","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,20]]},"reference":[{"key":"35223_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1164\/rccm.201701-0218PP","volume":"195","author":"CF Vogelmeier","year":"2017","unstructured":"Vogelmeier, C. F. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am. J. Respir. Crit. Care Med. 195, 557\u2013582. https:\/\/doi.org\/10.1164\/rccm.201701-0218PP (2017).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"35223_CR2","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/s0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095\u20132128. https:\/\/doi.org\/10.1016\/s0140-6736(12)61728-0 (2012).","journal-title":"Lancet"},{"key":"35223_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/s0140-6736(07)61380-4","volume":"370","author":"DM Mannino","year":"2007","unstructured":"Mannino, D. M. & Buist, A. S. Global burden of COPD: Risk factors, prevalence, and future trends. Lancet 370, 765\u2013773. https:\/\/doi.org\/10.1016\/s0140-6736(07)61380-4 (2007).","journal-title":"Lancet"},{"key":"35223_CR4","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.amjmed.2017.12.018","volume":"131","author":"A Anzueto","year":"2018","unstructured":"Anzueto, A. & Miravitlles, M. The role of fixed-dose dual bronchodilator therapy in treating COPD. Am. J. Med. 131, 608\u2013622. https:\/\/doi.org\/10.1016\/j.amjmed.2017.12.018 (2018).","journal-title":"Am. J. Med."},{"key":"35223_CR5","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1164\/rccm.201509-1869OC","volume":"193","author":"S Vedel-Krogh","year":"2016","unstructured":"Vedel-Krogh, S., Nielsen, F. S., Lange, P., Vestbo, J. & Nordestgaard, B. G. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease: The Copenhagen general population study. Am. J. Respir. Crit. Care Med. 193, 965\u2013974 (2016).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"35223_CR6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00120-2018","author":"S Vedel-Krogh","year":"2018","unstructured":"Vedel-Krogh, S., Nordestgaard, B. G., Lange, P., Vestbo, J. & Nielsen, S. F. Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.00120-2018 (2018).","journal-title":"Eur. Respir. J."},{"key":"35223_CR7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00164-2019","author":"D Singh","year":"2019","unstructured":"Singh, D. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: The GOLD science committee report 2019. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.00164-2019 (2019).","journal-title":"Eur. Respir. J."},{"key":"35223_CR8","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.jaip.2018.10.007","volume":"7","author":"CM Lee","year":"2019","unstructured":"Lee, C. M. et al. Inhaled corticosteroid-related tuberculosis in the real world among patients with asthma and COPD: A 10-year nationwide population-based study. J. Allergy Clin. Immunol. Pract. 7, 1197-1206 e1193. https:\/\/doi.org\/10.1016\/j.jaip.2018.10.007 (2019).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"35223_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002991.pub3","author":"IA Yang","year":"2012","unstructured":"Yang, I. A., Clarke, M. S., Sim, E. H. & Fong, K. M. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD002991.pub3 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"35223_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1183\/09031936.00193908","volume":"34","author":"C Crim","year":"2009","unstructured":"Crim, C. et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur. Respir. J. 34, 641\u2013647. https:\/\/doi.org\/10.1183\/09031936.00193908 (2009).","journal-title":"Eur. Respir. J."},{"key":"35223_CR11","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.2147\/COPD.S172240","volume":"13","author":"DP Tashkin","year":"2018","unstructured":"Tashkin, D. P. & Strange, C. Inhaled corticosteroids for chronic obstructive pulmonary disease: What is their role in therapy?. Int. J. Chron. Obstruct. Pulmon. Dis. 13, 2587\u20132601. https:\/\/doi.org\/10.2147\/COPD.S172240 (2018).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"35223_CR12","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1183\/09031936.00162313","volume":"43","author":"PR Burgel","year":"2014","unstructured":"Burgel, P. R. et al. Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: A paradigm shift in GOLD 2011?. Eur. Respir. J. 43, 1201\u20131203 (2014).","journal-title":"Eur. Respir. J."},{"key":"35223_CR13","doi-asserted-by":"publisher","first-page":"12004","DOI":"10.1038\/s41598-019-48355-2","volume":"9","author":"JH Park","year":"2019","unstructured":"Park, J. H. et al. Risk for pneumonia requiring hospitalization or emergency room visit according to delivery device for inhaled corticosteroid\/long-acting beta-agonist in patients with chronic airway diseases as real-world evidence. Sci. Rep. 9, 12004. https:\/\/doi.org\/10.1038\/s41598-019-48355-2 (2019).","journal-title":"Sci. Rep."},{"key":"35223_CR14","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1378\/chest.09-2992","volume":"139","author":"PMA Calverley","year":"2011","unstructured":"Calverley, P. M. A. et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest 139, 505\u2013512. https:\/\/doi.org\/10.1378\/chest.09-2992 (2011).","journal-title":"Chest"},{"key":"35223_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12931-018-0874-0","volume":"19","author":"DP Tashkin","year":"2018","unstructured":"Tashkin, D. P. et al. Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: A matched-subgroup post hoc analysis of the UPLIFT(R) trial. Respir. Res. 19, 196. https:\/\/doi.org\/10.1186\/s12931-018-0874-0 (2018).","journal-title":"Respir. Res."},{"key":"35223_CR16","doi-asserted-by":"publisher","first-page":"f3306","DOI":"10.1136\/bmj.f3306","volume":"346","author":"C Janson","year":"2013","unstructured":"Janson, C. et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: Observational matched cohort study (PATHOS). BMJ 346, f3306. https:\/\/doi.org\/10.1136\/bmj.f3306 (2013).","journal-title":"BMJ"},{"key":"35223_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105950","volume":"77","author":"M Yang","year":"2019","unstructured":"Yang, M., Du, Y., Chen, H., Jiang, D. & Xu, Z. Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials. Int. Immunopharmacol. 77, 105950. https:\/\/doi.org\/10.1016\/j.intimp.2019.105950 (2019).","journal-title":"Int. Immunopharmacol."},{"key":"35223_CR18","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/s2213-2600(18)30368-0","volume":"6","author":"S Suissa","year":"2018","unstructured":"Suissa, S., Dell\u2019Aniello, S. & Ernst, P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: A population-based cohort study. Lancet Respir. Med. 6, 855\u2013862. https:\/\/doi.org\/10.1016\/s2213-2600(18)30368-0 (2018).","journal-title":"Lancet Respir. Med."},{"key":"35223_CR19","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.chest.2019.03.005","volume":"155","author":"S Suissa","year":"2019","unstructured":"Suissa, S., Dell\u2019Aniello, S. & Ernst, P. Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice. Chest 155, 1158\u20131165. https:\/\/doi.org\/10.1016\/j.chest.2019.03.005 (2019).","journal-title":"Chest"},{"key":"35223_CR20","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.2147\/COPD.S286149","volume":"15","author":"JH Lee","year":"2020","unstructured":"Lee, J. H. et al. Risk of pneumonia associated with inhaled corticosteroid in patients with chronic obstructive pulmonary disease: A Korean Population-Based Study. Int. J. Chron. Obstruct. Pulmon. Dis. 15, 3397\u20133406. https:\/\/doi.org\/10.2147\/COPD.S286149 (2020).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"35223_CR21","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson, D. A. et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 378, 1671\u20131680. https:\/\/doi.org\/10.1056\/NEJMoa1713901 (2018).","journal-title":"N. Engl. J. Med."},{"key":"35223_CR22","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.2147\/COPD.S143656","volume":"12","author":"C Janson","year":"2017","unstructured":"Janson, C., Stratelis, G., Miller-Larsson, A., Harrison, T. W. & Larsson, K. Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 12, 3055\u20133064. https:\/\/doi.org\/10.2147\/COPD.S143656 (2017).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35223-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35223-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35223-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T12:04:50Z","timestamp":1684584290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35223-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,20]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["35223"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-35223-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,20]]},"assertion":[{"value":"6 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EGL and YIH have no conflict of interest. CKR received consulting and lecture fees from MSD, AstraZeneca, GlaxoSmithKline, Novartis, Takeda, Mundipharma, Boehringer-Ingelheim, TEVA, Sanofi, and Bayer. KHY has conducted clinical trials in Asthma, COPD, and Pneumonia with GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim, Novartis, Takeda, Nycomed, TEVA, MSD, Mundipharma, Hyundai Ankook, Chongkendang, Hanmi, and Hanlym. He received consulting fees from GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim, Novartis, Mundipharma, Ankook, Chongkendang, Hanmi, and Hanlym. YBP received consulting and lecture fees from AstraZeneca, GlaxoSmithKline, Novartis, Mundipharma, Boehringer-Ingelheim, and Sanofi. SEL was a former employee of Boehringer-Ingelheim Korea. KYJ was a former employee of Boehringer-Ingelheim Korea. YK received consulting and lecture fees from MSD, GlaxoSmithKline, Boehringer-Ingelheim, and Hanlim.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8183"}}